Back to Browse Journals » Core Evidence » Volume 7

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation

Authors Lee N, Wald A

Published Date June 2012 Volume 2012:7 Pages 39—47

DOI http://dx.doi.org/10.2147/CE.S25240

Received 13 April 2012, Accepted 1 May 2012, Published 25 June 2012

Noel Lee, Arnold Wald

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Abstract: Both irritable bowel syndrome (IBS), characterized by chronic and recurrent abdominal pain and altered bowel habits, and functional constipation are highly prevalent gastrointestinal problems for which many patients seek medical advice. A diverse number of treatment approaches are currently recommended to treat persons with chronic constipation as well as patients with IBS in which constipation is the main gastrointestinal symptom (IBS-C). These approaches have had somewhat limited success, and many patients remain dissatisfied with available therapy. Recently, linaclotide, a novel intestinal secretagogue, which works by activating the guanylate cyclase C receptor on the luminal surface of the intestinal epithelium, has been demonstrated to be efficacious in patients with both chronic functional constipation and with IBS-C in a series of randomized, placebo-controlled studies in these populations. Evidence for this assertion is provided in this systematic review of the pharmacologic properties of this novel agent and the published pivotal studies which support the efficacy of this agent in targeted populations.

Keywords: linaclotide, constipation, irritable bowel syndrome, safety, efficacy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency

Nakajima K, Oshida H, Muneyuki T, Kakei M

Core Evidence 2012, 7:77-91

Published Date: 19 July 2012

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Zoellner Y, Balp MM, Gili Marco A

ClinicoEconomics and Outcomes Research 2011, 3:109-116

Published Date: 4 August 2011

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma

Brian Poligone, Janet Lin, Catherine Chung

Core Evidence 2011, 6:1-12

Published Date: 22 December 2010

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008